Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy
- 1 July 2010
- journal article
- research article
- Published by Elsevier in Epilepsy & Behavior
- Vol. 18 (3) , 229-237
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Mental Health (K23 MH066835)
This publication has 30 references indexed in Scilit:
- An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsyExpert Opinion on Investigational Drugs, 2007
- Once-Daily OROS ® Methylphenidate Is Safe and Well Tolerated in Adolescents With Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2006
- ADHD Rating Scale-IV: Checklists, Norms, and Clinical InterpretationJournal of Psychoeducational Assessment, 2006
- Attention deficit and hyperactivity disorder, methylphenidate, and epilepsyArchives of Disease in Childhood, 2005
- Which factors may play a pivotal role on determining the type of psychiatric disorder in children and adolescents with epilepsy?Epilepsy & Behavior, 2004
- Use of Methylphenidate for Attention-Deficit Hyperactivity Disorder in Patients With Epilepsy or Electroencephalographic AbnormalitiesJournal of Child Neurology, 2003
- ADHD and epilepsy in childhoodDevelopmental Medicine & Child Neurology, 2003
- Prevalence, Classification, and Severity of Epilepsy in Children in Western NorwayEpilepsia, 2000
- Epilepsy and attention deficit hyperactivity disorder: Is methylphenidate safe and effective?The Journal of Pediatrics, 1997
- Proposal for Revised Classification of Epilepsies and Epileptic SyndromesEpilepsia, 1989